Population-Based Estimates of Cancer and Mortality in Barrett's Esophagus: Implications for the Future

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 9, 2011, Pages 723-724

  Wani, Sachin ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RISK; CARDIA; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COLON CANCER; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DYSPLASIA; EDITORIAL; ENDOSCOPY; ERADICATION THERAPY; ESOPHAGEAL ADENOCARCINOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INCIDENCE; MORTALITY; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT CARE; POPULATION; SMALL INTESTINE CANCER;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE;

EID: 80052026893     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.05.025     Document Type: Editorial

References (14)

1. Pohl H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005, 97:142-146.
2. Shaheen N.J., Crosby M.A., Bozymski E.M., et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 2000, 119:333-338.
3. Wani S., Puli S.R., Shaheen N.J., et al. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol 2009, 104:502-513.
4. Wani S., Falk G., Hall M., et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011, 9:220-227.
5. de Jonge P.J., van Blankenstein M., Looman C.W., et al. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010, 59:1030-1036.
6. Schouten L.J., Steevens J., Huysentruyt C.J.R., et al. Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2011, 9:754-761.
7. Wani S., Mathur S., Sharma P. How to manage a Barrett's esophagus patient with low-grade dysplasia. Clin Gastroenterol Hepatol 2009, 7:27-32.
8. Curvers W.L., ten Kate F.J., Krishnadath K.K., et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010, 105:1523-1530.
9. Wani S., Falk G.W., Sampliner R.E., et al. Low grade dysplasia is a poor marker for cancer progression in patients with Barrett's esophagus: preliminary results from a large, multicenter, cohort study. Gastroenterology 2009, 136(Suppl 1):A592.
10. Anderson L.A., Murray L.J., Murphy S.J., et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 2003, 52:1081-1084.
11. Jung K.W., Talley N.J., Romero Y., et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol 2011, in press.
12. Sikkema M., de Jonge P.J., Steyerberg E.W., et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010, 8:235-244.
13. Inadomi J.M., Somsouk M., Madanick R.D., et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009, 136:2101-2114.
14. Spechler S.J., Sharma P., Souza R.F., et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011, 140:1084-1091.